TB-500 and thymosin beta-4: why the name on the vial is not enough

Author and reviewer: Dr. Sarah Chen, PhD Pharmacology.

Posted on 26 October 2026

TB-500 is a name used in peptide discussions and product listings associated with thymosin beta-4. The exact material matters: research on a full peptide, a fragment or an ophthalmic formulation cannot automatically be applied to every product sold under a related name.

Are TB-500 and thymosin beta-4 the same?

Do not assume they are interchangeable without checking the specification. A 2012 analytical paper identified a preparation called TB-500 as an acetylated fragment corresponding to part of thymosin beta-4. Its purpose was detection in equine samples, not proving a treatment benefit in people. (Ho et al., 2012)

A later analytical study also described products claiming to contain either a synthetic fragment or thymosin beta-4 itself. That is a practical reason to identify the sequence and form rather than rely on a short commercial name. (Delcourt et al., 2025)

Why does the distinction change the evidence?

Imagine a paper studies one defined molecule while a listing supplies another. Even a well-conducted experiment cannot directly establish the behaviour of the second substance. The mismatch is present before questions about dose, delivery or study quality arise.

For a research reader, record the exact peptide identity first. Next record the formulation and experimental setting. Only then assess whether the paper answers the question being asked. This prevents a long bibliography from creating an appearance of support through studies of related but different materials.

What does the human dry-eye trial show?

A 2015 randomised study tested thymosin beta-4 eye drops in 72 people with dry eye over 28 days. Neither primary endpoint showed a significant difference at the specified assessment; several secondary measures did. These were ocular outcomes for an ophthalmic preparation. (Sosne & Ousler, 2015)

Why primary and secondary outcomes matter

The primary outcome is the main question designated by a trial. Secondary outcomes provide additional information. When the main result is negative but some secondary measures are positive, readers need both facts. The secondary findings may justify further investigation without resolving the original question.

This does not mean a study is worthless. It means the next experiment should be designed around the remaining uncertainty, instead of turning a selective result into a blanket claim.

Can TB-500 research be used to recommend a BPC-157 blend?

A combination introduces another question. Evidence for either component alone does not establish the combined product's effects, interactions or safety. The appropriate evidence would identify the actual combination and test outcomes relevant to the claim.

What should I check in the next paper I read?

Keep a five-line note: identity, model, route, primary outcome and limitation. If a summary skips the first three, it is difficult to know what the result applies to. If it omits the last two, it is difficult to know how much confidence the result deserves.

For TB-500 peptide searches, this habit is especially useful because a familiar name can hide meaningful differences in the underlying material. This article appraises selected studies; it does not establish a personal treatment use.